Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nemvaleukin Alfa,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Alkermes Plc
Deal Size : Not Applicable
Deal Type : Not Applicable
Mural Oncology Announces Enhancements to Late-Stage Clinical Trials
Details : Nemvaleukin is a IL-2 variant designed to harness anti-cancer capabilities of high-dose rhIL-2, currently in phase 3 clinical development for treating platinum-resistant epithelial ovarian cancer.
Brand Name : ALKS 4230
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 08, 2024
Lead Product(s) : Nemvaleukin Alfa,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Alkermes Plc
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?